pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 3·1 min read
save

Bristol Myers Squibb assesses AI spending after deploying tools to thousands of staff

Jun 3, 2026·read at Endpoints ↗Neutral

Bristol Myers Squibb has recently provided artificial intelligence applications to a large portion of its workforce.

The company is now turning its attention to measuring the cost of these tools and identifying where they deliver productivity gains.

Executives say the analysis will help determine which AI solutions are worth scaling and which may be trimmed.

The effort reflects a broader industry trend of evaluating the financial impact of AI as firms expand digital capabilities.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Bristol Myers turns focus to AI costs after broad rollout to workers”

read at Endpoints ↗
90 words · retrieved Jun 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOL4BRISTOL MYERS SQUIBB3BRISTOL MYERS SQUIBB CO3

related stories

  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive
  • May 29Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksBioPharma Dive
  • May 19STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much moreSTAT
  • May 18STAT+: Supreme Court rejects challenge to Medicare drug price negotiationSTAT
  • May 18Regeneron immunotherapy combo comes up short in melanoma trialBioPharma Dive